2023-07-16-世界卫生组织-Immunization_Palestine_2023_country_profile_20页_376kb

报告摘要

For most vaccines, the National/National 12-month administrative and survey (agency-adjusted) coverage estimates remain robust across many years, indicating good routine immunization system performance.
All 2022 coverage estimates (baseline or revised) are remarkably high, near universal coverage (>95%), reflecting steady state for many immunization program indicators.
Some estimates from 2005, 2012, 2017, and 2018 show notable gains, with scheduled mechanisms covering critical immunity thresholds effectively.
Four vaccines have estimates showing uncertainties (noted challenges or adjusted data): DTP3, RCV1, HepB3, and MCV1 for 2022. Deterministic methods (intervals) were not available to quantify uncertainty formally from this user.
HIV vaccine is not practiced.
Extensive supplementary survey data has been integrated into estimates for 2017-2023 across multiple vaccines, providing richer determinants for immunization success at district level (environmental health factors, etc.).

展开完整摘要